480 related articles for article (PubMed ID: 10585007)
21. Comparison of docetaxel and docetaxel-irinotecan combination as second-line chemotherapy in advanced non-small-cell lung cancer: a randomized phase II trial.
Pectasides D; Pectasides M; Farmakis D; Kostopoulou V; Nikolaou M; Gaglia A; Koumpou M; Mylonakis N; Xiros N; Economopoulos T; Raptis SA
Ann Oncol; 2005 Feb; 16(2):294-9. PubMed ID: 15668287
[TBL] [Abstract][Full Text] [Related]
22. New chemotherapeutic agents for the treatment of non-small cell lung cancer: the Japanese experience.
Saijo N
Chest; 1998 Jan; 113(1 Suppl):17S-23S. PubMed ID: 9438685
[TBL] [Abstract][Full Text] [Related]
23. A phase II study of docetaxel-irinotecan combination in advanced pancreatic cancer.
Kurtz JE; Négrier S; Husseini F; Limacher JM; Borel C; Wagner JP; Prévot G; Bergerat JP; Dufour P
Hepatogastroenterology; 2003; 50(50):567-70. PubMed ID: 12749274
[TBL] [Abstract][Full Text] [Related]
24. Phase II study of docetaxel alternating with cisplatin in chemotherapy-naïve patients with advanced non-small cell lung cancer.
Mattson K; Vansteenkiste J; Stupp R; Bargetzi M; Saarinen A; Jekunen A; Fillet G; Teixeira M; Gatzemeier U; Olivares R; Soussan-Lazard K; Bérille J
Anticancer Drugs; 2000 Jan; 11(1):7-13. PubMed ID: 10757557
[TBL] [Abstract][Full Text] [Related]
25. Phase I and pharmacologic study of docetaxel and irinotecan in advanced non-small-cell lung cancer.
Masuda N; Negoro S; Kudoh S; Sugiura T; Nakagawa K; Saka H; Takada M; Niitani H; Fukuoka M
J Clin Oncol; 2000 Aug; 18(16):2996-3003. PubMed ID: 10944133
[TBL] [Abstract][Full Text] [Related]
26. Phase I study of carboplatin, irinotecan and docetaxel on a divided schedule with recombinant human granulocyte colony stimulating factor support in patients with stage IIIB or IV non-small cell lung cancer.
Fujita A; Ohkubo T; Hoshino H; Takabatake H; Tagaki S; Sekine K
Anticancer Drugs; 2002 Jun; 13(5):505-9. PubMed ID: 12045462
[TBL] [Abstract][Full Text] [Related]
27. Phase II study of cisplatin combined to irinotecan administered alternatingly with docetaxel in advanced non-small cell lung cancer.
Charoentum C; Thongprasert S; Chewasakulyong B; Euathrongchit J; Sorraritchingchai S; Munprakan S
J Med Assoc Thai; 2007 Nov; 90(11):2506-12. PubMed ID: 18181342
[TBL] [Abstract][Full Text] [Related]
28. Docetaxel for previously treated non-small-cell lung cancer.
Fossella FV
Oncology (Williston Park); 2002 Jun; 16(6 Suppl 6):45-51. PubMed ID: 12108897
[TBL] [Abstract][Full Text] [Related]
29. Emerging role of docetaxel (Taxotere) in advanced non-small cell lung cancer.
Gandara DR; Edelman MJ; Lau D
Semin Oncol; 1999 Jun; 26(3 Suppl 10):3-7. PubMed ID: 10437743
[TBL] [Abstract][Full Text] [Related]
30. Phase II study of biweekly administration of docetaxel and irinotecan in patients with refractory or relapsed advanced non-small cell lung cancer.
Hirose T; Shirai T; Ishida H; Ando K; Sugiyama T; Kusumoto S; Hosaka T; Nakashima M; Ohmori T; Adachi M
Cancer Chemother Pharmacol; 2007 Jul; 60(2):267-74. PubMed ID: 17273827
[TBL] [Abstract][Full Text] [Related]
31. A Phase II NCCTG study of irinotecan and docetaxel in previously treated patients with non-small cell lung cancer.
Molina JR; Nikcevich D; Hillman S; Geyer S; Drevyanko T; Jett J; Verdirame J; Tazelaar H; Rowland K; Wos E; Kutteh L; Nair S; Fitch T; Flynn P; Stella P; Adjei AA
Cancer Invest; 2006; 24(4):382-9. PubMed ID: 16777690
[TBL] [Abstract][Full Text] [Related]
32. Single agents in the second-line treatment of non-small cell lung cancer.
Belani CP
Semin Oncol; 1998 Jun; 25(3 Suppl 8):10-4. PubMed ID: 9704670
[TBL] [Abstract][Full Text] [Related]
33. Phase I study of carboplatin, docetaxel and irinotecan with recombinant human granulocyte colony stimulating factor support in patients with advanced non-small cell lung cancer.
Fujita A; Takabatake H; Tagaki S; Sekine K
Anticancer Drugs; 2000 Nov; 11(10):821-4. PubMed ID: 11142689
[TBL] [Abstract][Full Text] [Related]
34. Paclitaxel in lung cancer: 1-hour infusions given alone or in combination chemotherapy.
Hainsworth JD; Greco FA
Semin Oncol; 1995 Dec; 22(6 Suppl 15):45-9. PubMed ID: 8643970
[TBL] [Abstract][Full Text] [Related]
35. Overview of docetaxel (Taxotere)/cisplatin combination in non-small cell lung cancer.
Le Chevalier T; Bérille J; Zalcberg JR; Millward MJ; Monnier A; Douillard JY; McKeage MJ; James R; Soulas F; Loret C; Bougon N; Bizzari JP
Semin Oncol; 1999 Jun; 26(3 Suppl 11):13-8. PubMed ID: 10458205
[TBL] [Abstract][Full Text] [Related]
36. Phase I study of weekly CPT-11 (irinotecan)/docetaxel in patients with advanced solid tumors.
Font A; Sanchez JM; Rosell R; Taron M; Martinez E; Guillot M; Manzano JL; Margeli M; Barnadas A; Abad A
Lung Cancer; 2002 Aug; 37(2):213-8. PubMed ID: 12140145
[TBL] [Abstract][Full Text] [Related]
37. Phase I study of docetaxel and irinotecan in patients with advanced non-small-cell lung cancer.
Nogami N; Harita S; Ueoka H; Yonei T; Kiura K; Kamei H; Tabata M; Segawa Y; Gemba K; Tanimoto M
Lung Cancer; 2004 Jul; 45(1):85-91. PubMed ID: 15196738
[TBL] [Abstract][Full Text] [Related]
38. Overview of docetaxel (Taxotere) in the treatment of non-small cell lung cancer.
Fossella FV
Semin Oncol; 1999 Jun; 26(3 Suppl 11):4-8. PubMed ID: 10458203
[TBL] [Abstract][Full Text] [Related]
39. Docetaxel (Taxotere) in the neo-adjuvant setting in non-small-cell lung cancer.
Mattson K
Ann Oncol; 1999; 10 Suppl 5():S69-72. PubMed ID: 10582143
[TBL] [Abstract][Full Text] [Related]
40. Docetaxel and radiation as combined-modality therapy.
Kim ES; Khuri FR
Oncology (Williston Park); 2002 Jun; 16(6 Suppl 6):97-105. PubMed ID: 12108904
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]